Q3 Earnings Estimate for TG Therapeutics Issued By B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at B. Riley boosted their Q3 2025 earnings per share estimates for shares of TG Therapeutics in a research report issued to clients and investors on Monday, May 5th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will earn $0.40 per share for the quarter, up from their prior estimate of $0.26. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics’ FY2026 earnings at $1.50 EPS, FY2027 earnings at $2.54 EPS and FY2028 earnings at $3.67 EPS.

A number of other research firms also recently issued reports on TGTX. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.80.

TG Therapeutics Trading Down 0.6 %

TGTX opened at $33.64 on Thursday. TG Therapeutics has a fifty-two week low of $15.16 and a fifty-two week high of $46.48. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The company’s 50-day moving average is $38.90 and its 200 day moving average is $33.56. The firm has a market capitalization of $5.34 billion, a PE ratio of -336.37 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company’s revenue was up 90.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.07) EPS.

Hedge Funds Weigh In On TG Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. CWM LLC lifted its holdings in TG Therapeutics by 16.2% during the first quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 290 shares during the last quarter. Arizona State Retirement System raised its stake in shares of TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock valued at $1,283,000 after purchasing an additional 364 shares during the period. Blue Trust Inc. increased its position in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 371 shares during the period. Golden State Wealth Management LLC lifted its stake in TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 433 shares in the last quarter. Finally, Summit Investment Advisors Inc. raised its position in shares of TG Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company’s stock worth $440,000 after buying an additional 463 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.